Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces regulatory filing of Saroglitazar Magnesium for treatment of NASH with DCGI

Posted On: 2019-12-06 13:36:40

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has filed the NDA of Saroglitazar Mg in Non-alcoholic Steatohepatitis (NASH) with the Drug Controller General of India (DCGI).

NASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatment of NASH. Starting with fat accumulation in liver, this condition can progress to cirrhosis and liver failure. NASH ranks as one of the major causes of cirrhosis, behind hepatitis C and alcoholic liver disease. Liver transplantation is the only option for managing advanced cirrhosis with liver failure.

"There is a significant need for new therapies for patients with NASH, who have no treatment options as their liver disease progresses, other than opting for eventual liver transplants to survive" said Pankaj R. Patel, Chairman, Zydus group said, "We are very pleased that our NDA filing has been accepted for review which we believe represents an important step towards providing an innovative treatment option for millions of patients suffering from this devastating liver disease."

Saroglitazar Magnesium was launched in India during September 2013, for the treatment of hypertriglyceridemia and diabetic dyslipidemia in patients with type-2 diabetes not controlled by statins. Saroglitazar Mg has demonstrated beneficial effects in NASH animal models. Saroglitazar Mg favorably affects all components of NASH including steatosis, ballooning, inflammation and fibrosis in NASH models. Saroglitazar Mg has previously demonstrated improvement in both liver enzymes along with favorable effects on lipid and glycemic indices in patients with nonalcoholic fatty liver disease in Phase II clinical trials.

Zydus had also achieved positive results in EVIDENCES II Phase 3 biopsy-driven trial of Saroglitazar 4 mg versus Placebo in patients with Non-Alcoholic SteatoHepatitis. The primary endpoint evaluated the histological improvement of NASH using liver biopsy at the end of 52 weeks. Separately, the results of EVIDENCES IV trial of Saroglitazar Mg in patients with NASH were presented as a Late Breaker at The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.256.65 as compared to the previous close of Rs. 263.35. The total number of shares traded during the day was 27733 in over 517 trades.

The stock hit an intraday high of Rs. 264 and intraday low of 256.65. The net turnover during the day was Rs. 7223917.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Blue Dart Sales at Rs. 855.64 crores for the Quarter October - December 2019

L&T Finance Holdings Ltd consolidated Q3 net profit up at Rs. 591.03 crore

RIL Q3 FY20 consolidated PAT at Rs. 11640 crore

Country's best-selling multi-purpose van Maruti Suzuki Eeco is now BS6 compliant

Aegon Life Insurance Company partners with Saksoft to accelerate digital transformation

CRISIL Rating on the Rs.5000 Crore Infrastructure Bonds of Axis Bank Limited

Capri Global Capital Ltd to divest stake in ARC arm

Mahindra First Choice Wheels Ltd to acquire www.carandbike.com

Mercator Ltd has sold vessel for Rs. 49.54 crore

Yash Chemex Ltd to apply for IPO of Hindprakash Industries Ltd

HCL Technologies Ltd Board approves Dividend of Rs. 2 for FY2019-20

TCS board declares third interim dividend of Rs. 5 for FY2020

United Drilling Tools Ltd launched truck mounted winch with crane

APL Apollo Tubes Limited approves allotment of Commercial Paper of Rs 20 Crores

Quick Heal Technologies Ltd gets favorable verdict from CESTAT

Acrysil Limited Signs An Agreement With Farah Ali Khan For Brand STERNHAGEN

IOB files insolvency application against Ramky Infrastructure subsidiary

HCL Technologies Ltd posts consolidated net profit of Rs. 2944 crores in Q3 FY20

L&T Technology Services Ltd reports consolidated PAT of Rs. 204.1 crore in Q3

TCS Q3 FY20 consolidated PAT at Rs. 8118 crore

AVANTEL Ltd Q3 net profit at Rs. 2.90 crore

Accel Ltd to acquire 75% of Computer Factory India Pvt. Ltd.

Piramal Divests its DRG Business for US$950 Million

Rubfila International Ltd to acquire 50% of Premier Tissues India Ltd

QGO Finance Ltd to raise Rs. 11 crore through NCDs

AMAL Ltd Q3 net profit at Rs. 1.36 crore

Trident Limited received 'TEXPROCIL Export Awards 2018-2019'

Manomay Tex India Limited wins TEXPROCIL Export Award 2018-19

Apollo Micro Systems Limited bags order of Rs. 18.10 crores

Kalpataru Power Transmission Ltd successfully commissions element 1 of Alipurduar Transmission Ltd

Srikalahasthi Pipes Ltd commences commercial operations of ferro alloys unit

Karnataka Bank's net profit at Rs. 123.14 crores in Q3 FY2020

Rallis reports positive performance with Consolidated Revenues at Rs. 534 Crores, up 28% QoQ Consolidated PAT at Rs. 38 Crores, up 177% QoQ

5paisa Capital - Income for Q3FY20 at Rs. 2,678 Lakhs (up 48% y-o-y), and for 9MFY20 at Rs. 7,289 Lakhs (up 83% y-o-y)

The Hon'ble Supreme Court of India lifts suspension of the Environment Clearance on GMR Goa International Airport

Bharti Airtel evaluates filing curative petition on AGR verdict

CARE reaffirms FD rating of Gillanders Arbuthnot and Company Limited

Dishman Carbogen Amcis Ltd Board approves Buy-back of equity shares upto Rs. 150 through market purchase

Hitech Corporation Ltd to discontinue operations at Sarigam unit

HIL Ltd to sell calcium silicate insulation products division

TATA Metaliks Ltd Q3 net profit jumps to Rs. 45.91 crores

Karnataka Bank Ltd Q3 net profit at Rs. 123.14 crores

South Indian Bank Ltd posts PAT of Rs. 90.54 crores in Q3 FY2020

Rallis India Ltd reports consolidated net profit of Rs. 38.14 crores in Q3

Cyient Limited Q3 consolidated PAT up at Rs. 108.3 crore

IndiGo strengthens connectivity between India and the Middle-East with Dammam as its 24th international destination

TCS Named a Leader in Healthcare Digital Services by Avasant

Wipro Ventures Announces $150M Fund II to Invest in Emerging Digital Enterprise Software Leaders

Sterling and Wilson Solar Limited wins 'Utility-Scale Solar Project of the Year' at Middle East Solar Awards 2020

Ind-Ra downgrades rating of Rico Auto Industries Ltd







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019